INNOVATE (NRG-GU008): A randomized phase III trial of salvage radiotherapy and androgen deprivation therapy (ADT) with/without abiraterone and apalutamide for patients with node-positive prostate cancer after radical prostatectomy.

Ronald C. Chen,Theodore Karrison,Colleen A. Lawton,William A. Hall,Hala T. Borno,Mihaela Rosu,Ashesh B. Jani,David M. Schuster,Michael J. Seider,Jason A. Efstathiou,Edwin M. Posadas,Paul L. Nguyen,Felix Y. Feng

INNOVATE (NRG-GU008): A randomized phase III trial of salvage radiotherapy and androgen deprivation therapy (ADT) with/without abiraterone and apalutamide for patients with node-positive prostate cancer after radical prostatectomy.

2021

Ronald C. Chen
Theodore Karrison
Colleen A. Lawton
William A. Hall
Hala T. Borno
Mihaela Rosu
Ashesh B. Jani
David M. Schuster
Michael J. Seider
Jason A. Efstathiou
Edwin M. Posadas
Paul L. Nguyen
Felix Y. Feng

TPS179Background: Node-positive prostate cancer comprises for approximately 13% of newly-diagnosed patients and represents an aggressive form of the disease, but has been historically understudied ...

Keywords:

Apalutamide
Disease
Oncology
Prostate cancer
Abiraterone
Prostatectomy
Androgen deprivation therapy
Internal medicine
salvage radiotherapy
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations